drugset
drugset / Trial / NCT02200718

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis

NCT02200718 ↗

Phase 1 Unknown 12 enrolled Immune Response BioPharma, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

A Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis to demonstrate safety \& efficacy

Timeline

Start
2020-12-31
Primary completion
2024-11-09
Completion
2024-11-09

Drugs

EvaluationDrugModalityDoseRoute
Subject NeuroVax Vaccine — —

Indications

multiple sclerosis